Healthcare & Life Sciences

• Advise on pharmaceutical, medical device, healthcare, cosmetic, food and dietary food regulations

• Provide antitrust and compliance advice to domestic and multinational pharmaceutical companies, medical device companies and medical institutions

• Advise on alcohol and tobacco regulations

• Advise on drug and medical device pricing & reimbursement under the National Health Insurance system

• Advise on clinical trial related matters

• Advise on corporate transactions of pharmaceutical and medical device industries including:

• - Bayer’s Mercilon business transfer to Alvogen Korea

• - Lotus Pharma’s equity investment in Alvogen Korea

• - Baxter’s spin-off of Baxalta business

• - Shire and Baxalta merger transaction

• - Johnson & Johnson’s acquisition of Pfizer’s consumer healthcare business

• - 3M’s sale of its pharmaceutical business in Korea

• - Celltrion’s acquisition of Hanskin

Corporate

• Advised LS Cable & System Asia on the sale of its stake to investors

• Advised SeAH Steel on tis spin-off of sheet metal business

• Advised SeAH Network on its sale of Dremline to an investor

• Advised Dongwon F&B on its acquisition of a meat processing company

• Advised Sehkoy Semiconductor New Material on its acquisition of UP Chemical

• Advised Bodyfriend on the sale of its stake to investors

• Advised LG Household and Health Care on its acquisition of Diamond spring water

• Advised WPP Group on its acquisition of Korean advertising companies including OSO, Pharmax and Digital Ocean

• Advised CJ on its sale of household business

Fair Trade

• Represent clients in Korea Fair Trade Commission’s investigations into pharmaceutical and medical devices industry

• Represent clients in reverse payment cases

• Represent a client in mobile phone handset collusion investigation

• Represent a client in hotel collusion case

• Represent a client in ramen collusion case

Education

• Advise on establishment foreign educational institution in Korea

• Advise on structural reform of universities in Korea

• Digital Health (Korea chapter), International Comparative Legal Guides (2023-24)
• Pharma & Medical Device Regulation (Korea chapter), Getting the Deal Trough, Lexology (2022-24)
• The Healthcare Law Review (Korea chapter), The Law Reviews (2022-24)
• Distribution and Marketing of Drugs (Korea chapter): A Global Guide From Practical Law (2018, 2015, Thomson Reuters)
• Practical Law Multi-Jurisdictional Guide: Life Sciences (Korea chapter, 2012-2015)
• “Medical Advertisement and Inducement of Patients” (Legal Times, 2012)
• The International Comparative Legal Guide to Pharmaceutical Advertising (Korea chapter, 2009)
• A Study on the Criteria for Establishing Foreign Educational Institutions in Overseas Countries based on the Analysis of the Criteria for Establishing Universities in Each Country (Co-researcher, Korea Research Foundation, 2020)
• Exit Strategy and Working Manual for Promoting University Structural Reform (Co-researcher, Ministry of Education, 2016)
• Transfer of Management Rights of School Foundation (Principal researcher, Korea University Institute for Higher Education Policy, 2014)
• “Clinical Trials and Compliance”, Joint Seminar by Korean Research-based Pharma Industry Association and Korea Medical Devices Industry Association (2022)
• “CP Issues in Interactions with Patients and Patient Organizations”, Ethical Business Workshop, Korea Pharmaceutical and Bio-Pharma Manufacturers Association (2022)
• “Trends in Government Investigation into the Pharmaceutical Industry”, Breakfast Seminar for Pharmaceutical Industry Executives hosted by Deloitte Korea (2018)
• “Expenditure Report under the Korean Sunshine Act”, Korea Medical Devices Industry Association (2018)
• “One Year after the Implementation of the Anti-Graft Act and Trends in Kickback Investigations”, Korea Medical Devices Industry Association (2017)
• “Key Issues in and Strategy for Contract Negotiations”, Korea Pharmaceutical Advanced Institution (2017)
• “Understanding Global Business Agreements for Pharmaceutical Companies”, Korea Human Resource Development Institute for Health & Welfare (2017)
• “Transforming Risk into Value: How to Respond to the Anti-Graft Act?”, Deloitte World Class Compliance Workshop (2016)
• “Interactions with Patients and Patient Organizations”, Korean Research-based Pharma Industry Association (2015)
• 2015 KRPIA Ethical Business Practice Workshop (panelist)
• “The License-Patent Linkage System and Antitrust Issues), Spring Conference of Korea Society of Food, Drug and Cosmetics (2015)
• “Understanding Domestic and International Regulation on the Advertisement of Medical Services”, Korea Human Resource Development Institute for Health & Welfare (2014)
• 2014 KRPIA Ethical Business Practice Workshop (panelist)
• “Proactive Negotiation in Cross-border Contracts”, Korea Human Resource Development Institute for Health & Welfare (2014)
• “Business Partnership”, Korea Drug Research Association (2014)
• 2013 KRPIA Ethical Business Practice Workshop (panelist)
• “M&A Transactions: Pharmaceutical Industry in Korea”, Conference for Global Alliance and M&A Strategy, Korea Pharmaceutical Manufacturers Association (2013)
• 2012 KRPIA Ethical Business Practice Workshop (panelist)
• “Fair Trade Issues in the Pharmaceutical Industry”, Seoul Bar Antitrust Committee Seminar (2011)
• “Healthcare Regulation Reform and Compliance Issues”, In-House Counsel Forum (2010)
• “Unfair Customer Inducement Issues in the Pharmaceutical Industry”, Seoul Bar (2010)
• “Case Study on Drug Advertising”, Korean Research-based Pharma Industry Association (2006)